La Jolla, CANCT07017699Now EnrollingIRB Ready

Psoriasis (PsO) Clinical Trial in La Jolla, CA

Access cutting-edge psoriasis (pso) treatment through this clinical trial at a research site in La Jolla. Study-provided care at no cost to qualified participants.

Sponsored by Bristol-Myers Squibb

Quick Self-Assessment

See if you qualify for this La Jolla location

Preparing your pre-screening questions…

Expert Care in La Jolla

Access psoriasis (pso) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related psoriasis (pso) treatment provided free

Apply for This La Jolla Location

Check if you qualify for this psoriasis (pso) clinical trial in La Jolla, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to La Jolla

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit La Jolla site if eligible
  4. 4Begin participation

About This Psoriasis (PsO) Study in La Jolla

The purpose of this study is to assess pregnancy and infant outcomes among pregnant participants enrolled in an established North American pregnancy registry (Organization of Teratology Information Specialists \[OTIS\]) who were exposed to deucravacitinib.

Sponsor: Bristol-Myers Squibb

Who Can Participate

Inclusion Criteria

Cohort 1: Deucravacitinib-exposed cohort
Currently pregnant during the enrollment period
Diagnosed with psoriasis (PsO) validated by medical records when possible
Exposure to deucravacitinib for any number of days, at any dose, and at any time from 2 days prior to date of conception (DOC) to the end of pregnancy
Agree to the conditions and requirements of the study including the interview schedule, release of medical records, and the dysmorphology examination of live born infants Cohort 2: PsO Disease-matched unexposed comparator cohort
Currently pregnant during the enrollment period
Diagnosed with PsO validated by medical records when possible
May be exposed to systemic treatments for PsO
Agree to the conditions and requirements of the study including the interview schedule, release of medical records, and the dysmorphology examination of live born infants Cohort 3: Non-disease unexposed comparator cohort
Currently pregnant during the enrollment period
Agree to the conditions and requirements of the study including the interview schedule, release of medical records, and the dysmorphology examination of live born infants

Exclusion Criteria

Cohort 1: Deucravacitinib-exposed cohort
Pregnant women who have enrolled in this cohort study with a previous pregnancy
Pregnant women who have used deucravacitinib for an indication other than PsO
Women who do not have exposure to deucravacitinib anytime from 2 days prior to DOC to the end of pregnancy
Women who have exposure to another oral tyrosine kinase 2 (TYK2) inhibitor or any oral Janus kinase (JAK) inhibitor from within 5 half-lives of DOC to the end of pregnancy
Women who have exposure to methotrexate or an oral retinoid
Retrospective enrollment after the outcome of pregnancy is known (ie, the pregnancy has ended prior to enrollment)
Results of a diagnostic test are positive for an major congenital malformation(s) (MCM) prior to enrollment. However, women who have had any normal or abnormal prenatal screening or diagnostic test prior to enrollment are eligible as long as the test result does not indicate an MCM Cohort 2: Disease-matched unexposed comparator cohort
Pregnant women who have enrolled in this cohort study with a previous pregnancy
Women who have exposure to deucravacitinib or any other oral TYK2 inhibitor except deucravacitinib, or any oral JAK inhibitor from within 5 half-lives of DOC to the end of pregnancy
Women who have exposure to methotrexate or an oral retinoid
Retrospective enrollment after the outcome of pregnancy is known (ie, the pregnancy has ended prior to enrollment)
Results of a diagnostic test are positive for an MCM prior to enrollment. However, women who have had any normal or abnormal prenatal screening or diagnostic test prior to enrollment are eligible as long as the test result does not indicate an MCM Cohort 3: Non-disease unexposed comparator cohort
Pregnant women who have enrolled in this cohort study with a previous pregnancy
Women who have had exposure to deucravacitinib or any other oral TYK2 inhibitor, or any oral JAK inhibitor from within 5 half-lives of DOC to the end of pregnancy
Retrospective enrollment after the outcome of pregnancy is known (ie, the pregnancy has ended prior to enrollment)
Results of a diagnostic test are positive for an MCM prior to enrollment. However, women who have had any normal or abnormal prenatal screening or diagnostic test prior to enrollment are eligible as long as the test result does not indicate an MCM
Women exposed to a known, possible, or suspected human teratogen during pregnancy as confirmed by the OTIS Research Center (see Appendix 3 for list of known, possible, and suspected human teratogens)
Women who are diagnosed with PsO, or any other autoimmune disease

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in La Jolla?

Yes, this clinical trial (NCT07017699) has an active research site in La Jolla, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Psoriasis (PsO) Treatment Options in La Jolla, CA

If you're searching for psoriasis (pso) treatment options in La Jolla, CA, this clinical trial (NCT07017699) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our La Jolla research site is actively enrolling participants for this clinical trial. You'll receive care from experienced psoriasis (pso) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all psoriasis (pso) clinical trials near you to find additional studies recruiting in your area.

More Psoriasis Trials in La Jolla, CA

See all psoriasis clinical trials recruiting in La Jolla — not just this study.

Browse Psoriasis Trials in La Jolla →

Browse More Trials by Condition

Psoriasis TrialsAnkylosing Spondylitis TrialsAll Conditions →

Ready to Join in La Jolla?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · La Jolla, CA